Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Bristol’s merger headaches may be contagious

  • Matthew Herper

By Matthew Herper June 24, 2019

Reprints
Alex Hogan/STAT

If any pharma CEO is still intoxicated by the idea of a megamerger, the rough Monday Bristol-Myers Squibb (BMY) is having could be an antidote.

The company announced that in order to assuage the Federal Trade Commission’s concerns about its $74 billion purchase of rival Celgene (CELG), it will seek to sell Celgene’s blockbuster psoriasis treatment Otezla.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Matthew Herper

Matthew Herper

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

Tags

Revenge of the gaslit patients: Now, as scientists, they’re…
Revenge of the gaslit patients: Now, as scientists, they’re tackling Ehlers-Danlos syndromes
Common injections don’t help knee osteoarthritis more than placebo,…
Common injections don’t help knee osteoarthritis more than placebo, large data review finds
23andMe had devastating news about my health. I wish…
23andMe had devastating news about my health. I wish a person had delivered it
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War

Recommended Stories